US/UK/Canada

Share

Contacts

  • Hansa Biopharma AB
    Scheelevägen 22 22363 Lund, Sweden
    +46 (0) 461 656 70
    http://www.hansabiopharma.com
    • Pick a time period -
    Tags ( Active)

    Successful desensitization with IdeS in all recruited patients in ongoing US Phase II study

    Hansa Medical AB (publ) today announced that additional data from the ongoing US Phase II study with IdeS in kidney transplantation was presented at the 2016 American Transplant Congress (ATC) in Boston on June 14 at 6:00 pm (EDT).The ongoing Phase II study at Cedars Sinai Medical Center is an investigator-initiated study that is looking at the effects of IdeS in enabling kidney transplantation in highly sensitized kidney transplant patients. Recruitment for the study will be up to 20 patients. The data presented by the study’s principal investigator Professor Stanley Jordan, shows that

    Ongoing US study shows that IdeS allows for transplantation of highly sensitized patients

    An initial evaluation of the ongoing US study with IdeS at Cedars Sinai Medical Center shows that IdeS completely eliminates donor specific antibodies and allows for kidney transplantation in all sensitized patients. These results are for four patients that were included in the US study as of January 2016. As of today 10 patients have been treated and subsequently transplanted. Initial results from the study will be presented by Professor Stanley Jordan, the study’s principal investigator, at the 2016 American Transplant Congress (ATC) in Boston on June 14 at 6:00 pm.The ongoing Phase II

    Hansa Medical AB (publ) - Year-End Report 2015

    Several significant milestones reached in 2015January – December 2015 in summary – Highlights October – December · Hansa Medical’s shares began trading on Nasdaq Stockholm on November 2, 2015 · Data from the first patient in the ongoing US study with IdeS in highly sensitized patients presented at Hansa Medical’s Capital Markets Day on November 13, 2015, showed that one dose of IdeS effectively inactivates donor specific antibodies · Data published in Journal of Immunology shows that IdeS temporarily can silence B-cells, preventing B-cells from developing into antibody

    Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies

    At Hansa Medical’s Capital Markets Day in Stockholm today, one of the world’s leading transplantation experts, Professor Stanley Jordan at Cedars-Sinai Medical Center, Los Angeles, will show data from one of his ongoing studies where highly sensitized patients are desensitized and treated with Hansa Medical’s lead candidate drug IdeS prior to transplantation.Data will be shown from a patient with a PRA level of 100% who was treated and transplanted successfully in July this year. The investigator-sponsored clinical phase II study, which was initiated and led by Dr. Jordan, is an open-

    First patient in IdeS study at Cedars-Sinai Medical Center in Los Angeles receives kidney transplantation

    Hansa Medical AB (publ) today announced that the first patient in an investigator-sponsored Phase II clinical study at Cedars-Sinai Medical Center in Los Angeles, California, has been treated with IdeS and subsequently transplanted.The study is an open-label study to assess the safety and efficacy of IdeS in eliminating donor specific antibodies and thus prevent antibody-mediated rejection in highly sensitized patients. The study will include up to 20 highly sensitized patients on the UNOS (United Network for Organ Sharing) waiting list. The principal investigator, Professor Stanley

    Professor Stanley Jordan, a leading expert in transplant immunology, initiates IdeS-study in USA

    Hansa Medical AB (publ) today announced that a new study with its lead compound IdeS, currently in Phase II clinical studies, would be performed at Cedars-Sinai Medical Center in Los Angeles, California. The first patient will be included shortly.Hansa Medical AB (publ) today announced that a new study with its lead compound IdeS, currently in Phase II clinical studies, would be performed at Cedars-Sinai Medical Center in Los Angeles, California. The first patient will be included shortly. As previously announced, Dr. Jordan, the principal investigator, has submitted an IND for IdeS in

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media